Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias

Drug Safety

Volumn 30, Issue 10, 2007, Pages 891-898

  Pariente, Antoine ^a,b,c   Gregoire, Fleur ^c   Fourrier Reglat, Annie ^a,b,c   Haramburu, Fraņcoise ^b,c   Moore, Nicholas ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM U657   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CERIVASTATIN; CLOZAPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; OLANZAPINE; PERGOLIDE; RISPERIDONE; SULPIRIDE;

ARTICLE; CONFIDENCE INTERVAL; DATA BASE; DISPROPORTIONALITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FRANCE; HUMAN; MASS MEDIUM; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; STATISTICAL PARAMETERS; STROKE; TUBERCULOSIS; VALVULAR HEART DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; ANTIPSYCHOTIC AGENTS; ANTIRHEUMATIC AGENTS; DATABASES, FACTUAL; DOPAMINE AGONISTS; FRANCE; HEART VALVE DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; PERGOLIDE; PREJUDICE; PRODUCT SURVEILLANCE, POSTMARKETING; RHABDOMYOLYSIS; STROKE; TUBERCULOSIS;

EID: 34748847390     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730100-00007     Document Type: Article

References (23)

1. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54 (4): 315-21
2. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10 (6): 483-6
3. Roux E, Thiessard F, Fourrier A, et al. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed 2005; 9 (4): 518-27
4. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 (1): 3-10
5. Waller PC, Coulson RA, Wood SM. Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Saf 1996; 5 (6): 363-75
6. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44 (5): 513-8
7. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13 (8): 519-23
8. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12 (4): 271-81
9. Hauben M, Reich L, Van Puijenbroek EP, et al. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 2006; 62 (11): 967-70
10. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16 (4): 359-65
11. Strom LB. Pharmacoepidemiology. 4th ed. Chichester: Wiley, 2005
12. van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol 2001; 52 (5): 579-86
13. Begaud B. Dictionary of pharmacoepidemiology. Chichester: John Wiley & sons, 2000
14. Communiqué de presse: REMICADE® (infliximab)/Tuberculose. 2000 Dec 28. Agence Française de Sécurité Sanitaire des Produits de Santé [online]. Available from URL: http://afssaps.sante.fr/ htm/10/filcoprs/indcompr.htm [Accessed 2007 Aug 9]
15. Mac Carty EP, for Bayer Corporation. Market withdrawal of Baycol® (cerivastatin). 2001 Aug 8. US FDA [online]. Available from URL: http://www.fda.gov/medWatch/safety/2001/Baycol2.htm [Accessed 2007 Aug 9]
16. Ravoire S, for Lilly France. Information importante de pharmacovigilance Celance® (pergolide). Agence Française de Sécurité Sanitaire des Produits de Santé [online]. Available on URL: http://agmed.sante.gouv.fr/htm/10/filcoprs/041102.htm [Accessed 2007 Aug 9]
17. Communiqué de presse: Sécurité d'emploi des neuroleptiques chez les patients âgés atteints de démence. 2004 Mar 9. Agence Française de Sécurité Sanitaire des Produits de Santé [online]. Available from URL: http://afssaps.sante.fr/ htm/10/filcoprs/indcompr.htm [Accessed 2007 Aug 9]
18. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64 (2): 134-43
19. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170 (9): 1395
20. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2 (8463): 1056-8
21. Moore N, Noblet C, Kreft-Jais C, et al. French pharmacovigilance database system: examples of utilisation [in French]. Therapie 1995; 50 (6): 557-62
22. Kramer M. Clinical epidemiology and biostatistics. Berlin: Springer Verlag, 1988
23. Griffin JP, Weber JC. Voluntary systems of adverse reaction reporting - part I. Adverse Drug React Acute Poisoning Rev 1985; 4 (4): 213-30